Phase 2 N=39 Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Head and Neck Cancer
Primary: Clinical Response Rate Following Induction Chemotherapy — 10; 20; 9 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=69 Phase II Study of Concurrent C225, Cisplatin and Radiation in Stage IV Squamous Cell Carcinoma of the Head and Neck
Head and Neck Cancer
Primary: 2-year Progression-free Survival Rate — 47 proportion of participants
Phase 2 N=26 Radiotherapy, Carboplatin/Paclitaxel and Nivolumab for High Risk HPV-related Head and Neck Cancer
Oropharynx Squamous Cell Carcinoma
Primary: Progression-free Survival (PFS) — 65 percentage of patients
Phase 2 N=72 Chemotherapy and Locoregional Therapy Trial (Surgery or Radiation) for Patients With Head and Neck Cancer
HPV-Related Squamous Cell Carcinoma · HNSCC
Primary: Evaluate the Tumor Shrinkage (%) to Measure the Deep Response Rate (DRR) — 25; 26; 0 Participants
Phase 2 N=34 Phase II Treatment Stratification Trial Using Neck Dissection-Driven Selection to Improve Quality of Life for Low Risk Patients With HPV+ Oropharyngeal Squamous Cell Cancer
Oropharyngeal Squamous Cell Cancer
Primary: Median Change in Quality of Life (QOL) From Baseline to 12 Months Post Treatment — -4.2; 0; 6.3; 10.7 score on a scale
N/A N=7 Surgery With or Without Adjuvant Stereotactic Body Radiotherapy
Head and Neck Cancer
Primary: 1-year Local Control — NA; NA months
Phase 2 N=72 Involved Field Elective Volume De-Intensification Radiation Therapy for Head and Neck Cancer
Head and Neck Cancer · Carcinoma, Squamous Cell · Neoplasms, Oral
Primary: Number of Patients With Solitary Elective Volume Recurrence — 0 Participants
Phase 2 N=40 Adjuvant De-Escalated Radiation + Adjuvant Nivolumab for Intermediate-High Risk P16+ Oropharynx Cancer
Carcinoma, Squamous Cell of Head and Neck · Oropharynx Squamous Cell Carcinoma
Primary: One-year Progression-free Survival (PFS) — 97.50 percentage of participants
Phase 2 N=34 Nivolumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma That Can Be Removed by Surgery
Name Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma · Stage II Oropharyngeal Squamous Cell Carcinoma · Stage III Hypopharyngeal Squamous Cell Carcinoma
Primary: Pathologic Complete Response Rate — 45.5 percentage of complete response
Phase 2 N=14 Weekly Carboplatin, Paclitaxel and Cetuximab Treatment for Patients With Recurrent or Metastatic SCCHN
Head and Neck Cancer · Squamous Cell Carcinoma of the Head and Neck
Primary: Median Overall Survival — 231 Days
Phase 2 N=74 Cetuximab, Chemotherapy, and Radiation Therapy for Operable Stage III or IV Head and Neck Cancer
Head and Neck Cancer
Primary: Event-free Survival Rate at 1 Year — 0.79 proportion of patients
Phase 2 N=6 Induction TPN Followed by Nivolumab With Radiation in Locoregionally Advanced Laryngeal and Hypopharyngeal Cancer
Head and Neck Cancer
Primary: Median Laryngectomy-free Survival (LFS) — 11.1 months
Phase 2 N=20 Quad Shot Radiotherapy in Combination With Immune Checkpoint Inhibition
Advanced Head and Neck Squamous Cell Carcinoma · Recurrent Head and Neck Squamous Cell Carcinoma · Metastatic Head-and-neck Squamous-cell Carcinoma
Primary: Overall Response - — 40.0 percentage of participants
Phase 2 N=60 Treatment De-Intensification for Squamous Cell Carcinoma of the Oropharynx
Squamous Cell Carcinoma of Oropharynx
Primary: Percentage of Patients Free of Grade 3+ Late Toxicity — 86 percentage of participants
Phase 2 N=62 Intensity-Modulated Radiation Therapy & Nivolumab for Recurrent or Second Primary Head & Neck Squamous Cell Cancer
Recurrent Head and Neck Squamous Cell Carcinoma
Primary: Number of Participants With Progression-Free Survival (PFS) — 27 Participants
Phase 2 N=33 Fluorouracil, Hydroxyurea, Cetuximab and Twice-daily Intensity Radiation Therapy for Advanced Head and Neck Cancer
Head and Neck Cancer · Cancer of the Pharynx · Cancer of the Larynx
Primary: Llocoregional Recurrence — 27 Participants
Phase 2 N=43 Erlotinib, Docetaxel, and Radiation Therapy in Stage III or Stage IV Squamous Cell Carcinoma of the Head and Neck
Head and Neck Cancer
Primary: Percent of Participants With Disease-Free Survival (DFS) at 3 Years — 69.5 Percent
Phase 2 N=48 Mitomycin C in Patients With Incurable p16 Positive Oropharyngeal and p16 Negative Head and Neck Squamous Cell Carcinoma (HNSCC) Resistant to Standard Therapies
Squamous Cell Carcinoma of the Head and Neck · Squamous Cell Carcinoma, Head and Neck
Primary: Tumor Response Rate (TRR) — 3; 0 Participants
Phase 1 N=59 Pembrolizumab in Combination With CRT for LA-SCCHN
Head and Neck Cancer · Squamous Cell Carcinoma · Oral Cavity Cancer
Primary: Adverse Events Will be Assessed and Graded Using CTCAE 4.0. Occurrences With Max Grade and Percentage/Number of Participants Affected by AEs Will be Provided. — 57…
Phase 2 N=48 Re-irradiation With Fractionated Stereotactic Radiosurgery Plus Cetuximab in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck
Squamous Cell Carcinoma of the Head and Neck
Primary: 1-year Local Progression-free Survival (PFS) — 60 percentage of participants
Phase 2 N=114 De-intensification of Radiation and Chemotherapy for Low-Risk HPV-related Oropharyngeal SCC: Follow-up Study
Carcinoma, Squamous Cell · Head and Neck Neoplasms · Oropharyngeal Neoplasms
Primary: 2 Year Progression Free Survival After De-intensified Chemoradiotherapy (CRT) in Human Papilloma Virus (HPV)-Positive and/or p16 Positive Low-risk Oropharyngeal Squamous…
Phase 2 N=60 Cetuximab, Paclitaxel, Carboplatin & Radiation for Esoph, Gastroesoph & Gastric Cancer
Esophageal Cancer · Gastric Cancer
Primary: Reponse Rate at Time of Surgery by Tissue — 40 participants
Phase 2 N=61 Phase II Trial of Preoperative Combined Modality Therapy for Esophageal Carcinoma: Cisplatin-Irinotecan Followed by Radiation Therapy With Concurrent Cisplatin and Irinotecan.
Esophageal Carcinoma
Primary: Pathologic Complete Response — 55 participants
Phase 3 N=145 Combination Chemotherapy and Radiation in Treating Patients With Stage III or IV Head and Neck Cancer (Paradigm Trial)
Head and Neck Cancer
Primary: Overall Survival — 73; 78 percent of patients
Phase 2 N=46 Trial of Postoperative Radiation, Cisplatin, and Panitumumab in Locally Advanced Head and Neck Cancer
Cancer of Head · Cancer of Head and Neck · Cancer of Neck
Primary: Probability of Progression-free Survival (PFS) at 2 Years — 70 percentage of participants
Phase 2 N=238 Adjuvant Cetuximab and Chemoradiotherapy Using Either Cisplatin or Docetaxel in Treating Patients With Resected Stage III or Stage IV Squamous Cell Carcinoma or Lymphoepithelioma of the Head and Neck
Head and Neck Cancer
Primary: Disease-free Survival — 57.3; 65.9 percentage of participants — p=0.05
Phase 3 N=320 Radiation + Cisplatin or Panitumumab in Locally Advanced Stage III or Stage IV Head and Neck Cancer
Head and Neck Cancer
Primary: Progression-free Survival (PFS) Rate — 50; 43; 110; 117 Participants — p=0.83
Phase 2 N=35 Ph II Long Term/Low Dose Xeloda in Head and Neck Squamous Cell Carcinoma After Surgery, Radiation & or Chemo
Head and Neck Cancer
Primary: Compliance With Treatment . — 74 percentage of participants
Phase 2 N=90 Induction Chemotherapy Followed By Cetuximab and Radiation in HPV-Associated Resectable Stage III/IV Oropharynx Cancer
Head and Neck Cancer · Precancerous Condition
Primary: 24-month Progression-free Survival — 64 percentage of participants
Phase 2 N=22 Pembrolizumab Plus Docetaxel for the Treatment of Recurrent or Metastatic Head and Neck Cancer
Head and Neck Carcinoma
Primary: Overall Response Rate — 22.7 percentage